1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Abdominal Neoplasm: new trials by email Literature Review of Abdominal Neoplasm trials Research Report on Abdominal Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer AB-1015 - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 1 | Terminated | Arsenal Biosciences, Inc. | 19 | 2022-11-29 | 2026-10-29 |
Abdominal Neoplasms (2) · Genital Neoplasms, Female (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Epstein-Barr Virus Infections (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Bronchial Neoplasms (1)
Cell Count (1) · Docetaxel (1) · Irinotecan (1)
Arsenal Biosciences, Inc. (1) · Marengo Therapeutics, Inc. (1)
United States (2) · Canada (1) · France (1) · Spain (1)
2023 (1)